Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia.

× No keyword cloud information.

12 in total

1. Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma.

Authors: L P Koh; L C Lim; C H Thng
Journal: Med Oncol Date: 2000-08 Impact factor: 3.064

2. Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients.

Authors: M Ladetto; L Bergui; I Ricca; S Campana; A Pileri; C Tarella
Journal: Med Oncol Date: 2000-08 Impact factor: 3.064

3. Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma.

Authors: Saadettin Kilickap; Bunyamin Yavuz; Sercan Aksoy; Levent Sahiner; Murat Dincer; Hakan Harputluoglu; Mustafa Erman; Kudret Aytemir; Lale Tokgozoglu; Ibrahim Barista
Journal: Med Oncol Date: 2008-04-15 Impact factor: 3.064

4. Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma.

Authors: Junshik Hong; Ji Yeon Kim; Hee Kyung Ahn; Sang-Min Lee; Sun Jin Sym; Jinny Park; Eun Kyung Cho; Jeong Yeal Ahn; Sanghui Park; Sang Pyo Lee; Dong Bok Shin; Jae Hoon Lee
Journal: Support Care Cancer Date: 2012-10-31 Impact factor: 3.603

Review 5. Targeted B-cell depletion therapy in childhood-onset systemic lupus erythematosus: progress to date.

Authors: Stephen D Marks; Kjell Tullus
Journal: Paediatr Drugs Date: 2007 Impact factor: 3.022

6. Role of rituximab in first-line treatment of chronic lymphocytic leukemia.

Authors: Jeffrey Bryan; Gautam Borthakur
Journal: Ther Clin Risk Manag Date: 2010-12-22 Impact factor: 2.423

7. Rituximab and cytokine release syndrome.

Authors: Hrishikesh S Kulkarni; Pashtoon Murtaza Kasi
Journal: Case Rep Oncol Date: 2012-03-20

8. Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm.

Authors: S Vessillier; D Eastwood; B Fox; J Sathish; S Sethu; T Dougall; S J Thorpe; R Thorpe; R Stebbings
Journal: J Immunol Methods Date: 2015-05-07 Impact factor: 2.303

9. Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature.

Authors: Katsuhiro Makino; Jumi Nakata; Satoru Kawachi; Tatsuyuki Hayashi; Atsuo Nakajima; Munehiro Yokoyama
Journal: J Med Case Rep Date: 2013-12-30

10. A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Authors: J A Woyach; T S Lin; M S Lucas; N Heerema; M E Moran; C Cheney; D M Lucas; L Wei; M A Caligiuri; J C Byrd
Journal: Leukemia Date: 2009-02-19 Impact factor: 11.528